Unbound MEDLINE

fosamprenavir calcium journal articles from PubMed MEDLINE database

Unbound MEDLINE results for:RSS FEEDBookmark this site
fosamprenavir calcium| Refine this search
1 - 10 of 172 journal articles in the PubMed databaseEmail to a friend    
 
Tomillero A, Moral MA 
Gateways to clinical trials. [Journal Article]
Methods Find Exp Clin Pharmacol 2009 Sep; 31(7):463-93.
Abstract | Full Citation
Luber A, Condoluci D, Slowinski P, et al. 
Steady-state amprenavir and tenofovir pharmacokinetics after coadministration of unboosted or ritonavir-boosted fosamprenavir with tenofovir disoproxil fumarate in healthy volunteers. [JOURNAL ARTICLE]
HIV Med 2009 Oct 23.
Abstract | Full Citation | Find Related Articles 
Hill A, Sawyer W 
Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients. [Journal Article]
HIV Med 2009 Oct; 10(9):527-35.
Abstract | Full Citation | Find Related Articles 
De Clercq E 
The history of antiretrovirals: key discoveries over the past 25 years. [JOURNAL ARTICLE]
Rev Med Virol 2009 Aug 27; 19(5):287-299.
Abstract | Full Citation
Van Houtte M, Picchio G, Van Der Borght K, et al. 
A comparison of HIV-1 drug susceptibility as provided by conventional phenotyping and by a phenotype prediction tool based on viral genotype. [JOURNAL ARTICLE]
J Med Virol 2009 Aug 20; 81(10):1702-1709.
Abstract | Full Citation
Perrella A, Sbreglia C, D'Antonio A, et al. 
Fosamprenavir treatment in a highly active antiretroviral therapy schedule induces a HCV-RNA decrease and a Th1 network boost in HIV/HCV-coinfected patients. [JOURNAL ARTICLE]
Clin Microbiol Infect 2009 Jul 20.
Abstract | Full Citation | Find Related Articles 
Perez-Elias MJ, Larrousse Morellon M, Ortega E, et al. 
Pharmacokinetics of Fosamprenavir plus Ritonavir in HIV-1-infected Adult Subjects with Hepatic Impairment. [JOURNAL ARTICLE]
Antimicrob Agents Chemother 2009 Aug 10.
Abstract | Full Citation | Find Related Articles 
McRae M, Clay PG, Anderson PL, et al. 
Pharmacokinetics of concurrent administration of fosamprenavir and atazanavir without ritonavir in human immunodeficiency virus-negative subjects. [Journal Article, Research Support, Non-U.S. Gov't]
Pharmacotherapy 2009 Aug; 29(8):937-42.
Abstract | Full Citation
Parks DA, Jennings HC, Taylor C, et al. 
Steady-State Amprenavir, Tenofovir, and Emtricitabine Pharmacokinetics Before and After Reducing Ritonavir Boosting of a Fosamprenavir/Tenofovir/Emtricitabine Regimen from 200 mg to 100 mg Once Daily (TELEX II). [Journal Article]
HIV Clin Trials 2009 May-Jun; 10(3):160-7.
Abstract | Full Citation
Shuter J, Sarlo JA, Rode RA, et al. 
Occurrence of Selective Ritonavir Nonadherence and Dose-Staggering in Recipients of Boosted HIV-1 Protease Inhibitor Therapy. [Journal Article]
HIV Clin Trials 2009 May-Jun; 10(3):135-42.
Abstract | Full Citation
New Search Next Results
  
Stay current! Search Swine Flu Pandemic or subscribe to the Swine Flu RSS Feed

Advertise on this site.